A bibliometric analysis of metastatic breast cancer: two-decade report (2002-2022)
暂无分享,去创建一个
[1] B. Pistilli,et al. Antibody–Drug Conjugate Revolution in Breast Cancer: The Road Ahead , 2023, Current Treatment Options in Oncology.
[2] Shou-Ching Tang,et al. The race to develop oral SERDs and other novel estrogen receptor inhibitors: recent clinical trial results and impact on treatment options , 2022, Cancer metastasis reviews.
[3] B. Pistilli,et al. The Molecular Predictive and Prognostic Biomarkers in Metastatic Breast Cancer: The Contribution of Molecular Profiling , 2022, Cancers.
[4] F. Cardoso,et al. Progression-free survival and quality of life in metastatic breast cancer: The patient perspective , 2022, Breast.
[5] Amy M. Sitapati,et al. Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. , 2022, Journal of the National Comprehensive Cancer Network : JNCCN.
[6] Rishvanth K. Prabakar,et al. Disease characterization in liquid biopsy from HER2-mutated, non-amplified metastatic breast cancer patients treated with neratinib , 2022, NPJ breast cancer.
[7] J. Lemonnier,et al. Multimodal liquid biopsy for early monitoring and outcome prediction of chemotherapy in metastatic breast cancer , 2021, NPJ breast cancer.
[8] M. Somerfield,et al. Endocrine Treatment and Targeted Therapy for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer: ASCO Guideline Update , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] G. Curigliano,et al. The role of tyrosine kinase inhibitors in the treatment of HER2+ metastatic breast cancer. , 2021, European journal of cancer.
[10] A. Prat,et al. Current and Future Management of HER2-Positive Metastatic Breast Cancer. , 2021, JCO oncology practice.
[11] A. Jager,et al. Measuring Quality of Life Using Patient-Reported Outcomes in Real-World Metastatic Breast Cancer Patients: The Need for a Standardized Approach , 2021, Cancers.
[12] H. Rugo,et al. An Overview of PARP Inhibitors for the Treatment of Breast Cancer , 2021, Targeted Oncology.
[13] T. Schmid,et al. Hypoxia in Breast Cancer—Scientific Translation to Therapeutic and Diagnostic Clinical Applications , 2021, Frontiers in Oncology.
[14] K. Hanna,et al. Chemotherapy Treatment Considerations in Metastatic Breast Cancer , 2021, Journal of the advanced practitioner in oncology.
[15] A. Jemal,et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.
[16] G. Semenza,et al. Hypoxia-Induced Suppression of Alternative Splicing of MBD2 Promotes Breast Cancer Metastasis via Activation of FZD1 , 2021, Cancer Research.
[17] T. Vandenberg,et al. Everolimus in Advanced Breast Cancer: A Systematic Review and Meta-analysis , 2020, Targeted Oncology.
[18] Sung-Bae Kim,et al. Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] A. Le,et al. A Co-Citation and Co-Word Analysis of Social Entrepreneurship Research , 2020 .
[20] Gang Chen,et al. Current Trends in Research on Bone Regeneration: A Bibliometric Analysis , 2020, BioMed research international.
[21] C. Arteaga,et al. Overcoming Endocrine Resistance in Breast Cancer. , 2020, Cancer cell.
[22] A. Jemal,et al. Cancer statistics, 2020 , 2020, CA: a cancer journal for clinicians.
[23] M. Banys-Paluchowski,et al. Liquid biopsy in metastatic breast cancer , 2019, Cancer drug resistance.
[24] Sung-Bae Kim,et al. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer. , 2019, The New England journal of medicine.
[25] R. Hastings,et al. Plasma cell-free DNA (cfDNA) as a predictive and prognostic marker in patients with metastatic breast cancer , 2019, Breast Cancer Research.
[26] Joel S. Bader,et al. E-cadherin is required for metastasis in multiple models of breast cancer , 2019, Nature.
[27] S. Loi,et al. Neoadjuvant neratinib promotes ferroptosis and inhibits brain metastasis in a novel syngeneic model of spontaneous HER2+ve breast cancer metastasis , 2019, Breast Cancer Research.
[28] T. Fehm,et al. The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper. , 2019, Critical reviews in oncology/hematology.
[29] Eric P. Winer,et al. Breast Cancer Treatment: A Review , 2019, JAMA.
[30] E. D. de Vries,et al. Tumor-associated macrophages in breast cancer: Innocent bystander or important player? , 2018, Cancer treatment reviews.
[31] Soo-Chin Lee,et al. CDK4-6 inhibitors in breast cancer: current status and future development , 2018, Expert opinion on drug metabolism & toxicology.
[32] S. Mathoulin-Pélissier,et al. Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohort. , 2018, European journal of cancer.
[33] M. Robson,et al. Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation , 2017, The New England journal of medicine.
[34] T. Burki. Sacituzumab govitecan activity in advanced breast cancer. , 2017, The Lancet. Oncology.
[35] K. Gelmon,et al. Palbociclib and Letrozole in Advanced Breast Cancer. , 2016, The New England journal of medicine.
[36] Simak Ali,et al. Mutation Analysis of Cell-Free DNA and Single Circulating Tumor Cells in Metastatic Breast Cancer Patients with High Circulating Tumor Cell Counts , 2016, Clinical Cancer Research.
[37] Olivier Molinier,et al. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial , 2016, The Lancet.
[38] A. Harlev,et al. Bibliometrics: tracking research impact by selecting the appropriate metrics , 2016, Asian journal of andrology.
[39] A. Tzankov,et al. Role of the Tumor Microenvironment in Breast Cancer , 2015, Pathobiology.
[40] Sung-Bae Kim,et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. , 2015, The New England journal of medicine.
[41] J. Silverman,et al. HER2 in Breast Cancer: A Review and Update , 2014, Advances in anatomic pathology.
[42] M. Choti,et al. Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies , 2014, Science Translational Medicine.
[43] J. Baselga,et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. , 2012, The New England journal of medicine.
[44] Sung-Bae Kim,et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. , 2012, The New England journal of medicine.
[45] Robert A. Weinberg,et al. Tumor Metastasis: Molecular Insights and Evolving Paradigms , 2011, Cell.
[46] Judith Kamalski,et al. Finding a way through the scientific literature: indexes and measures. , 2011, World neurosurgery.
[47] G. Luisetto,et al. Endocrine therapy of breast cancer. , 2011, Current medicinal chemistry.
[48] J. Baselga,et al. CLEOPATRA: a phase III evaluation of pertuzumab and trastuzumab for HER2-positive metastatic breast cancer. , 2010, Clinical breast cancer.
[49] Karen Gelmon,et al. Metastatic behavior of breast cancer subtypes. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[50] T. Fehm,et al. Detection and HER2 Expression of Circulating Tumor Cells: Prospective Monitoring in Breast Cancer Patients Treated in the Neoadjuvant GeparQuattro Trial , 2010, Clinical Cancer Research.
[51] Ludo Waltman,et al. Software survey: VOSviewer, a computer program for bibliometric mapping , 2009, Scientometrics.
[52] C. Hudis. Trastuzumab--mechanism of action and use in clinical practice. , 2007, The New England journal of medicine.
[53] Brigitte Rack,et al. Detection of Circulating Tumor Cells in Peripheral Blood of Patients with Metastatic Breast Cancer: A Validation Study of the CellSearch System , 2007, Clinical Cancer Research.
[54] C. Parker,et al. Open-label phase II study evaluating the efficacy and safety of two doses of pertuzumab in castrate chemotherapy-naive patients with hormone-refractory prostate cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[55] D. Ribatti. The contribution of Gianni Bonadonna to the history of chemotherapy , 2007, Cancer Chemotherapy and Pharmacology.
[56] M. Berger,et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. , 2006, The New England journal of medicine.
[57] Chaomei Chen,et al. CiteSpace II: Detecting and visualizing emerging trends and transient patterns in scientific literature , 2006, J. Assoc. Inf. Sci. Technol..
[58] J. O’Shaughnessy. Extending survival with chemotherapy in metastatic breast cancer. , 2005, The oncologist.
[59] Y Wang,et al. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials , 2005, The Lancet.
[60] Alison Stopeck,et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. , 2004, The New England journal of medicine.
[61] A. Howell,et al. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[62] C K Osborne,et al. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[63] Y. Yarden,et al. Untangling the ErbB signalling network , 2001, Nature Reviews Molecular Cell Biology.
[64] Christian A. Rees,et al. Molecular portraits of human breast tumours , 2000, Nature.
[65] G. Hortobagyi,et al. Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[66] W Godolphin,et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. , 1989, Science.
[67] David C Christiani,et al. THE NEW ENGLAND JOURNAL OF MEDICINE , 1977, The Lancet.
[68] J. Nabarro,et al. THE NITROGEN MUSTARDS , 1950, The Journal of pharmacy and pharmacology.
[69] T. Ishikawa,et al. Increased intratumor heterogeneity, angiogenesis and epithelial to mesenchymal transition pathways in metaplastic breast cancer. , 2021, American journal of cancer research.
[70] A. Soyder,et al. The Relationship Between MRI Findings and Molecular Subtypes in Women With Breast Cancer. , 2019, Current problems in diagnostic radiology.
[71] A. Schneeweiss,et al. Chemotherapie desmetastasiertenMammakarzinoms – ein Anachronismus in der Ära der personalisierten zielgerichteten onkologischenTherapie ? Chemotherapy for Metastatic Breast Cancer – An Anachronism in the Era of Personalised and Targeted Oncological Therapy ? , 2015 .
[72] D. Lake,et al. High-Dose Chemotherapy in Breast Cancer , 2012, Drugs.
[73] D. Ribnikar,et al. Metastatic breast cancer. , 2014, Current opinion in oncology.
[74] M. Dowsett,et al. Comparison of the short-term biological effects of 7alpha-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)-nonyl]estra-1,3,5, (10)-triene-3,17beta-diol (Faslodex) versus tamoxifen in postmenopausal women with primary breast cancer. , 2001, Cancer research.
[75] W. McGuire,et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.